(S008) Use of Mobile Devices for Creation of Survivorship Care Plans

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

Christine E. Hill-Kayser, MD, Carolyn Vachani, AOCN, Margaret K. Hampshire, RN, Gloria A. DiLullo, APN, James M. Metz, MD; Perelman School of Medicine, University of Pennsylvania

Introduction: Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

Methods: We launched and made an internet tool publically available for the creation of survivorship care plans in 2007. Available at www.livestrongcareplan.com and through the OncoLink website, it provides customized guidelines for survivor care and is free for use by survivors and HCPs worldwide. With the ninth iteration of the care plan tool, launched in May 2012, the tool became available in a mobile use format. The tool is free and accessible via Apple iPhone and iPad.

Results: Since the launch of the internet-based tool in 2007, it has been used to create 34,669 care plans. Overall, HCPs have created about 40% of them. The demographics of survivors for whom care plans have been created have remained relatively stable (75% women, 81% Caucasian, median age 51 years, with breast cancer being the most common diagnosis). From May 2012 to October 2013, 11,946 total plans were created, 645 (5%) of which were created using MDs. Of the MD-created plans, the majority (97%) was created by survivors or their friends and families, with only 3% being created by HCPs. Of the users of the MD plan, 74% was female and 86% was Caucasian, with a median age at diagnosis of 48 years and a median current age of 52 years. The most common diagnosis for which MD plans were completed was breast cancer (42%), followed by lymphoma (5%), colon cancer (4%), and lung cancer (4%). Of all MD users, 11% reported having received some type of survivorship information, and 15% reported having received a written treatment summary; 4% had previously created or received a LIVESTRONG Care Plan. The median time for completion of the patient version of the MD plan was 8:07 minutes and 6:27 minutes for the HCP version. The experience with using the MD tool was evaluated as good-excellent by 92% of users.

Conclusions: For users with access, MDs appear to be feasible tools for care plan creation. Based on preliminary data, this represents a novel way to disseminate useful information to cancer survivors, particularly those who may have MD access but not computer access. Future plans will include efforts to inform HCPs about the existence of the MD plan, which may be useful in clinical settings when tablet devices are available.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Related Content